
If you care for a wound at home, you receive wound dressings on prescription. From 1 January 2027, a new legal definition of what counts as a dressing applies – and a long transitional period ends for wound gels and similar products.
Key points
- The Act to Stabilise Contribution Rates in Statutory Health Insurance (GKV-Beitragssatzstabilisierungsgesetz) of 24 July 2026 redefines dressings in § 31(1a) SGB V. The new version applies from 1 January 2027.
- Wound dressings that cover or absorb and in addition keep the wound moist, clean it, bind wound exudate or odours, do not stick to the wound or act against germs – for example with silver – will then expressly count as dressings.
- The transitional period for “other products for wound treatment” ends on 31 December 2026. After that, the health insurance fund only pays for them if the Federal Joint Committee (G-BA) has included them in Annex V of the Pharmaceuticals Directive.
- At present, the G-BA counts above all wound gels, creams, ointments and solutions as well as products containing honey among them. It is currently adapting its rules to the new law.
- In its opinion of 20 November 2026, the Bundesrat proposes adding certain protease-modulating wound dressings to the definition – according to its explanatory statement, this concerns wound dressings with sucrose octasulfate. This is a proposal, not a change in the law.
- If you are prescribed such a product, speak to your doctor’s practice before the turn of the year.
Dressings and “other products”: the difference
Under § 31(1) SGB V, people with statutory health insurance are entitled to dressings (Verbandmittel). These include classic compresses and bandages, but also modern wound dressings such as foam dressings or alginates. Your doctor prescribes them, and the health insurance fund (Krankenkasse) pays for them. How often a dressing is changed on chronic wounds is explained in the article How often to change a dressing on chronic wounds.
In addition, there are what are known as other products for wound treatment (sonstige Produkte zur Wundbehandlung). According to the description of the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), they actively intervene in wound healing through a pharmacological, immunological or metabolic action – that is, through metabolic or defence processes in the body. The health insurance fund only pays for such products if the G-BA has assessed their medical benefit and included them in Annex V of its Pharmaceuticals Directive (Arzneimittel-Richtlinie). It decides on a manufacturer’s application within 90 days.
A transitional period applies to products that were already reimbursed before the G-BA’s new rules. Under the Act to Extend Powers and Reduce Bureaucracy in Nursing Care (Gesetz zur Befugniserweiterung und Entbürokratisierung in der Pflege), which came into force on 1 January 2026, it runs until 31 December 2026.
The new definition from 1 January 2027
The GKV-Beitragssatzstabilisierungsgesetz of 24 July 2026, promulgated in the Federal Law Gazette (Bundesgesetzblatt) on 29 July 2026, rewrites § 31(1a) SGB V. Under Article 8(2) of the Act, this change comes into force on 1 January 2027. Dressings will still be items that cover damaged body surfaces, absorb body fluids from them, or both. What is new is an exhaustive list of additional properties: if such an item has one of them, it nevertheless remains a dressing:
“An item shall also be deemed a dressing if, in addition to one of the properties referred to in sentence 1, it 1. keeps wounds moist or cleanses wounds, 2. binds wound exudate or odours, 3. prevents adhesion to the wound or can be changed atraumatically, or 4. has an antimicrobial action in or on the human body.”
§ 31(1a), sentence 2 SGB V in the version applicable from 1 January 2027 (our translation)
Wound exudate is the fluid that a wound secretes. “Can be changed atraumatically” means that the dressing can be removed without injuring the wound again. “Antimicrobial” means that the dressing acts against germs.
What changes for wound dressings with silver
So far, the G-BA has only classified silver-containing wound dressings as dressings if the silver has no direct contact with the wound and is not released into it. From 2027, according to the wording of the law, it is sufficient for a covering or absorbent wound dressing to have an additional antimicrobial action in or on the body. The Federal Government justifies this by saying that dressings with an antimicrobial action are of great importance for care and should therefore be available for direct prescription.
What was removed in the Bundestag
The draft bill adopted by the Federal Cabinet on 29 April 2026 also listed products with a “protease-modulating” action – that is, products that influence certain enzymes in the wound. The Committee on Health removed this property. Its report states that for such products “it cannot be assumed outright that they are a dressing” (our translation).
What does the Bundesrat propose?
On 20 November 2026, the Bundesrat delivered its opinion on the draft Care Reorganisation Act (Pflegeneuordnungsgesetz). In it, the Bundesrat proposes replacing No. 4 of the new definition (printed paper (Drucksache) 587/26 (Beschluss), item 42). Under this proposal, a covering or absorbent wound dressing would also count as a dressing if it additionally “has a protease-modulating action without providing biologically active structural or matrix components, or has an antimicrobial action in or on the human body” (our translation). Under the proposal, the change would come into force on the day after the Care Reorganisation Act is promulgated.
According to the Bundesrat’s explanatory statement, this concerns wound dressings with the active substance sucrose octasulfate, which it says are expressly taken into account in the S3 guideline on the local therapy of hard-to-heal and/or chronic wounds. In its assessment, without the change they would drop out of direct standard care on 31 December 2026. Products with biologically active structural or matrix components such as collagen or hyaluronic acid are not to be covered.
An opinion is a proposal to the Federal Government and the Bundestag, not a change in the law. Whether the Bundestag takes it up is open. Unless the law is amended accordingly, the version quoted above, without “protease-modulating”, applies from 1 January 2027.
The transitional period ends: gels, creams and solutions
The new version of § 31(1a) no longer contains a transitional period. In its draft bill, the Federal Government expressly assumes that the period will expire at the end of 2026, and expects this to save around 180 million euros a year. From 1 January 2027, the health insurance fund will therefore only pay for other products for wound treatment if they are listed in Annex V.
Which product groups the G-BA currently regards as other products is set out in Part 3 of Annex Va to its Pharmaceuticals Directive (as of 11 October 2025). The list is expressly not exhaustive:
- semi-solid to liquid preparations that do not keep their shape – in particular gels, creams, ointments, solutions, emulsions and suspensions for wound treatment,
- products containing honey, if the honey touches the wound directly or releases components into the wound,
- products with the active substance sucrose octasulfate under the same conditions.
A hydrogel, on the other hand, is not automatically an other product: if it is applied to a carrier material, for example as a compress, it counts under Part 2 of Annex Va as a dressing with additional properties. The G-BA has announced that it will adapt its rules to the new legal definition and has begun its deliberations on this. How individual products will be classified from 2027 also depends on this decision.
For wounds, Annex V (as of 24 March 2026) has so far listed, among other things, individual wound irrigation solutions and one wound dressing for people with diabetic foot syndrome – each for a limited period and only for certain medically necessary cases.
What you can do now
- Look at your prescription and your packs. If they show a wound gel, a cream, ointment or irrigation solution, or a product containing honey, raise this with your doctor before the turn of the year.
- Ask whether the product is listed in Annex V or whether another product could be considered for your wound. Your doctor decides which product is prescribed.
- Wound dressings such as foam dressings, alginates, hydrocolloids or dressings with silver already count as dressings under Annex Va. As a rule, you do not need to do anything here.
- If your health insurance fund refuses to pay, you receive a formal decision (Bescheid). How to challenge it is explained in the article Appealing against a health insurance decision.
- You may still buy a product yourself that the health insurance fund no longer pays for – you then bear the costs alone.
Price moratorium for wound products until 2030
The Act contains a second rule for wound care, aimed at manufacturers: the so-called price moratorium (Preismoratorium). It does not prohibit price increases: if manufacturers raise the price of a dressing or of an other product for wound treatment above the level of 1 January 2026, the health insurance funds receive a discount equal to the price increase from 1 January 2027 to 31 December 2030 (§ 130a(3e) SGB V). From 1 July 2028, the reference price is raised every year in line with the inflation rate. This rule does not change anything about the entitlement to dressings.
Frequently asked questions
Will I still get my wound dressing with silver on prescription in 2027?
Yes, if the dressing covers the wound or absorbs fluid and additionally acts against germs: under the new definition, it then counts as a dressing. The details of the distinction are governed by the G-BA in its directive, which it is currently adapting.
Will the health insurance fund still pay for my wound gel?
The transitional period applies until 31 December 2026. After that, only if the gel is listed in Annex V of the Pharmaceuticals Directive. Hydrogel on a carrier material, for example as a compress, is different: it already counts as a dressing today.
What applies in 2027 to wound dressings with sucrose octasulfate?
That is still open. If the active substance touches the wound directly or is released into it, the G-BA has so far counted such products as other products; for these, the transitional period ends on 31 December 2026, after which the health insurance fund only pays for them if they are listed in Annex V. On 20 November 2026, the Bundesrat proposed adding to the definition in such a way that, according to its explanatory statement, these wound dressings remain part of standard care. Whether the Bundestag takes this up has not been decided. Speak to your doctor’s practice before the turn of the year.
Do I have to pay a co-payment for dressings?
Yes, from the age of 18. The co-payment (Zuzahlung) is 10 per cent of the price – currently at least 5 and no more than 10 euros per item, and from 1 January 2027 at least 7.50 and no more than 15 euros – never more than the item costs. More on this in the article Co-payment from 2027.
Why is the legislator changing the definition?
According to the explanatory statement of the draft bill, the term “dressing” is to be defined exhaustively in the law. Wound dressings that create an environment for healing that is as natural as possible or that act against germs are to be available for prescription without a separate benefit assessment. At the same time, the Act aims to limit the expenditure of the health insurance funds.
How PharmaCare helps
We deliver the wound dressings and dressing materials prescribed by your doctor discreetly to your home and bill your health insurance fund directly. Our qualified specialists advise you on suitable products – Monday to Friday from 8 am to 5 pm, free of charge, also via WhatsApp or Signal.
You can send us a photo of your prescription (Rezept) in advance; the original goes by post to PharmaCare GmbH, Raiffeisenallee 16, 82041 Oberhaching – the easiest way is with the free envelope from our downloads (in German). You will find an overview of what we offer under Wound care (in German).
0800 74 222 73WhatsAppSignalSources
- Act to Stabilise Contribution Rates in Statutory Health Insurance (GKV-Beitragssatzstabilisierungsgesetz) of 24 July 2026, Federal Law Gazette 2026 Part I No. 228 – Article 1 Nos. 12 and 48, Article 8 (in German)
- Federal Government’s draft bill (version adopted by the Federal Cabinet), Federal Ministry of Health – explanatory statement on Article 1 No. 12 and financial impact (in German)
- Recommendation for a decision and report of the Committee on Health, printed paper 21/7016, German Bundestag, 8 July 2026 (in German)
- Opinion of the Bundesrat on the draft Care Reorganisation Act, printed paper 587/26 (Beschluss) of 20 November 2026, Bundesrat – item 42 with explanatory statement (in German)
- § 31 SGB V – Medicines and dressings (version applicable until 31 December 2026) and § 61 SGB V – Co-payments, Federal Ministry of Justice (in German)
- Dressings and other products for wound treatment, Federal Joint Committee (in German)
- Annex Va to the Pharmaceuticals Directive: dressings and other products for wound treatment (as of 11 October 2025) and Annex V: medical devices eligible for prescription (as of 24 March 2026), Federal Joint Committee (in German)
- Other products for wound treatment can still be prescribed as before, National Association of Statutory Health Insurance Physicians (KBV), 8 January 2026 (in German)
Note: This article gives a general overview and does not replace medical or legal advice. Your health insurance fund or long-term care insurance fund decides on your entitlement. The text was written with the help of artificial intelligence; all information has been checked against the sources listed. As of: 21 November 2026.